BIOGEN INC (1BIIB.MI) Stock Price, Forecast & Analysis
Europe - Euronext Milan - BIT:1BIIB - US09062X1037 - Common Stock
1BIIB.MI Key Statistics, Chart & Performance
The current stock price of 1BIIB.MI is 143.15 EUR. In the past month the price decreased by -18.46%.
1BIIB.MI Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ARGX.BR | ARGENX SE | 72.89 | 48.33B | ||
| 1AE.DE | ARGENX SE | 72.72 | 48.22B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 20.56B | ||
| 2X1.DE | ABIVAX SA | N/A | 8.41B | ||
| ABVX.PA | ABIVAX SA | N/A | 8.44B | ||
| GLPG.AS | GALAPAGOS NV | N/A | 1.76B | ||
| 5CV.DE | CUREVAC NV | 5.09 | 996.15M | ||
| NANO.PA | NANOBIOTIX | N/A | 869.81M | ||
| PHIL.MI | PHILOGEN SPA | 21.14 | 704.68M | ||
| IVA.PA | INVENTIVA SA | N/A | 547.70M | ||
| ALCLS.PA | CELLECTIS | N/A | 453.47M | ||
| FYB.DE | FORMYCON AG | N/A | 423.20M |
Related stock screener links
About 1BIIB.MI
Company Profile
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 7,605 full-time employees. The firm is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. The company operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). The company is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. The company also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).
Company Info
BIOGEN INC
225 Binney Street
Cambridge MASSACHUSETTS US
Employees: 7605
Phone: 17814642000
BIOGEN INC / 1BIIB.MI FAQ
What does BIOGEN INC do?
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 7,605 full-time employees. The firm is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. The company operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). The company is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. The company also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).
What is the current price of 1BIIB stock?
The current stock price of 1BIIB.MI is 143.15 EUR. The price increased by 2.73% in the last trading session.
What is the dividend status of BIOGEN INC?
1BIIB.MI does not pay a dividend.
How is the ChartMill rating for BIOGEN INC?
1BIIB.MI has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
Which stock exchange lists 1BIIB stock?
1BIIB.MI stock is listed on the Euronext Milan exchange.
Should I buy 1BIIB stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on 1BIIB.MI.
What is the ownership structure of BIOGEN INC (1BIIB.MI)?
You can find the ownership structure of BIOGEN INC (1BIIB.MI) on the Ownership tab.
1BIIB.MI Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to 1BIIB.MI.
1BIIB.MI Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to 1BIIB.MI. 1BIIB.MI scores excellent points on both the profitability and health parts. This is a solid base for a good stock.
1BIIB.MI Financial Highlights
Over the last trailing twelve months 1BIIB.MI reported a non-GAAP Earnings per Share(EPS) of 14.53. The EPS increased by 2.51% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 15.98% | ||
| ROA | 5.51% | ||
| ROE | 8.84% | ||
| Debt/Equity | 0.35 |
1BIIB.MI Forecast & Estimates
42 analysts have analysed 1BIIB.MI and the average price target is 154.08 EUR. This implies a price increase of 7.63% is expected in the next year compared to the current price of 143.15.
For the next year, analysts expect an EPS growth of -5.79% and a revenue growth 1.35% for 1BIIB.MI